Drug Trial Radar · NCT05638126
Safety and Tolerance of Increased Doses of HRS-1780 Tablets in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Oct 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
96
Actual
Start
Feb 2, 2023
Primary completion
Dec 2023
Study completion Dec 2023
Sponsor
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled phase I clinical study. The primary objective is to evaluate the safety, tolerability, PK, and PD of single- and multiple-dose HRS-1780 in healthy subjects, and to evaluate the food effect on PK of HRS-1780.
Conditions
- Chronic Kidney Disease
Interventions
HRS-1780 table or placeboDrug
HRS-1780 table or placebo single dose
HRS-1780 table or placeboDrug
HRS-1780 table or placebo single dose with food effect
HRS-1780 table or placeboDrug
HRS-1780 table or placebo multiple dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess the incidence and severity of adverse events in healthy subjects after single and multiple doses of HRS-1780 tabletsTime frame: About a month from the first medication to the evaluation.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.